MDMA-assisted group therapy research in Israel
Support the first-ever study comparing group vs. individual MDMA-assisted therapy!
MAPS will retain a small percentage of all contributions, which helps cover the operating expenses MAPS incurs to offer the Fiscal Sponsorship Program, including online donation platform and payment processor fees and other indirect costs.
About the Project
This open-label, multi-site, randomized, non-inferiority study will evaluate the safety and effectiveness of group vs. individual MDMA-assisted therapy in PTSD patients diagnosed following the events on October 7, 2023.
The study aims to assess a group MDMA-assisted therapy protocol, assessing its safety, tolerability, and effectiveness compared to individualized MDMA-assisted therapy — an approach that could increase accessibility if found to be safe and effective.
About the Fiscally Sponsored Project Operators:
MAPS Israel is an independent, Israel-based non-profit organization founded in 2021, with the purpose of developing psychedelic research and educational programs in Israel that are legal, safe, ethical, culturally, socially, and medically informed. Their mission is to promote and support studies of new, groundbreaking treatments for post-traumatic stress disorder (PTSD), treatment-resistant depression (TRD), eating disorders, and other indications as well as study the effects of psychedelics on healthy individuals.
